GeneScience Pharmaceuticals - About the company
GeneScience Pharmaceuticals is a series B company based in Changchun (China), founded in 1996. It operates as a Provides genetically engineered pharmaceuticals products. GeneScience Pharmaceuticals has raised an undisclosed amount in funding from investors like New Alliance Capital, China Huarong Asset Management and IDG Capital. The company has 61 active competitors, including 19 funded and 14 that have exited. Its top competitors include companies like Senti Biosciences, CRISPR Therapeutics and 64x Bio.
Company Details
Provides genetically engineered pharmaceutical products. They use the technology of genetic engineering and recombinant technology to produce their several propriety like GenLei Jintropin (human growth hormone), Genfulin (rDNA origin), recombinant human granulocyte-macrophage stimulating factor gel for burn treatment, and octreotide acetate for child growth.
- Website
- www.gensci-china.com
- Email ID
- *****@gensci-china.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
1996
Location
Changchun, China
Stage
Series B
Latest Funding Round
Investors
Ranked
10th among 61 active competitors
Employee Count
1 - 10 as on Jul 01, 2024
Investment & Acquisitions
Similar Companies
Sign up to download GeneScience Pharmaceuticals' company profile
GeneScience Pharmaceuticals's funding and investors
GeneScience Pharmaceuticals has raised funding over 2 rounds. Its first funding round was on Mar 04, 2021. Its latest funding round was a Series A round on Mar 04, 2021 for $*****. 2 investors participated in its latest round. GeneScience Pharmaceuticals has 5 institutional investors.
Here is the list of recent funding rounds of GeneScience Pharmaceuticals:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 04, 2021 | 5179102 | Series A | 6885363 | 1745256 | 1126555 | 3380241 |
Mar 04, 2021 | 7591612 | Series B | 6401518 | 5654273 | 4057846 |
View details of GeneScience Pharmaceuticals's funding rounds and investors
GeneScience Pharmaceuticals' founders and board of directors
Founder? Claim ProfileGeneScience Pharmaceuticals' employee count trend
GeneScience Pharmaceuticals has 1 - 10 employees as of Jul 24. Here is GeneScience Pharmaceuticals's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
GeneScience Pharmaceuticals's Competitors and alternates
Top competitors of GeneScience Pharmaceuticals include Senti Biosciences, CRISPR Therapeutics and 64x Bio. Here is the list of Top 10 competitors of GeneScience Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Senti Biosciences 2016, San Francisco (United States), Public | Developer of cell-based therapies for cancer treatment | $158M | 68/100 | |
2nd | CRISPR Therapeutics 2013, Basel (Switzerland), Public | Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 64/100 | |
3rd | 64x Bio 2017, San Francisco (United States), Series A | Developer of cell lines and production technologies for advanced therapies | $59.6M | 60/100 | |
4th | Genprex 2009, Austin (United States), Public | Developer of therapeutics to treat cancer at molecular level | $3.11M | 60/100 | |
5th | Poseida Therapeutics 2015, San Diego (United States), Acquired | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 60/100 | |
6th | OXGENE 2011, Oxford (United Kingdom), Acquired | Provider of a platform for mammalian cell engineering | $28.1M | 59/100 | |
7th | ADARx Pharmaceuticals 2019, San Diego (United States), Series C | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts | $353M | 59/100 | |
8th | Aldevron 1998, Fargo (United States), Acquired | Manufacturing plasmid DNA, RNA, proteins, and enzymes for genomic medicine | - | 58/100 | |
9th | Logomix 2019, San Carlos (United States), Series A | Provider of genome engineering platform to create artificial cells | $22.6M | 57/100 | |
10th | GeneScience Pharmaceuticals 1996, Changchun (China), Series B | Provides genetically engineered pharmaceuticals products | - | 50/100 |
Looking for more details on GeneScience Pharmaceuticals's competitors? Click here to see the top ones
GeneScience Pharmaceuticals's Investments and acquisitions
GeneScience Pharmaceuticals has a total of 1 investment in Rani Therapeutics. GeneScience Pharmaceuticals has not made any acquisitions as of now.Reports related to GeneScience Pharmaceuticals
Here is the latest report on GeneScience Pharmaceuticals's sector:
News related to GeneScience Pharmaceuticals
Media has covered GeneScience Pharmaceuticals for a total of 3 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
•
ALK and GenSci Partner to Expand AIT Market in ChinaGlobeNewswire•Sep 17, 2025•ALK-Abello, GeneScience Pharmaceuticals
•
GenSci Launches Global Innovation Hub in ShanghaiGlobal FinTech Series•Dec 26, 2023•GeneScience Pharmaceuticals, Ccht
•
Gensci opens global innovation center in ShanghaiPR Newswire•Dec 25, 2023•GeneScience Pharmaceuticals
•
GenSci launches global innovation center in ShanghaiPR Newswire•Dec 25, 2023•GeneScience Pharmaceuticals
•
•
•
Rani raises $53M for clinical trials of its innovative pillBioSpectrum India•Feb 12, 2018•, Rani Therapeutics, GeneScience Pharmaceuticals, Shire and 6 others
Are you a Founder ?
FAQs about GeneScience Pharmaceuticals
Explore our recently published companies
- Setfin - Sao Paulo based, 2021 founded, Unfunded company
- 3E8 Robotics - San Francisco based, 2025 founded, Unfunded company
- Tndindia - Unfunded company
_1531899939020.png?format=webp&height=120&width=120)